BioPorto Reports 47% Q4 Revenue Surge, Eyes 2026 Expansion

Event summary

  • BioPorto's Q4 2025 revenue hit DKK 11.6M, up 47% YoY, driven by NGAL RUO sales in the U.S. and strategic distributor orders.
  • Full-year 2025 revenue reached DKK 40.3M, within guidance, with NGAL products accounting for 70% of total revenue.
  • 2026 guidance targets DKK 48-58M in revenue, with adjusted EBITDA loss narrowing to DKK 50-60M.
  • BioPorto aims to expand U.S. hospital adoption to over 60 by year-end 2026, up from 44 in 2025.
  • The company expects to submit a pre-submission package to the FDA by Q1 2026 for its adult validation study.

The big picture

BioPorto's strong Q4 2025 performance underscores the growing demand for its NGAL-based diagnostics, particularly in the U.S. market. The company's strategic focus on expanding hospital adoption and navigating regulatory hurdles reflects broader industry trends toward personalized and early-intervention diagnostics. With a clear path to reducing losses and achieving positive cash flow, BioPorto's ability to execute on its 'Forward' strategy will be critical in determining its long-term success in the competitive diagnostics space.

What we're watching

Market Expansion
Whether BioPorto can sustain its rapid U.S. hospital adoption rate and meet its 2026 target of over 60 active hospitals.
Regulatory Milestones
The pace at which BioPorto advances its adult validation study and secures FDA approval, which is critical for broader market access.
Financial Sustainability
How BioPorto manages its cash position and secures financing for 2027, as it aims to achieve positive cash flow by the second half of 2027.

Related topics

Diagnostics